Profile data is unavailable for this security.
About the company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
- Revenue in USD (TTM)117.00m
- Net income in USD-307.00m
- Incorporated2015
- Employees577.00
- LocationArcus Biosciences Inc3928 Point Eden WayHAYWARD 94545-3719United StatesUSA
- Phone+1 (510) 694-6200
- Fax+1 (302) 730-1370
- Websitehttps://arcusbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.27bn | 147.00 | -- | 3.47 | -- | 61.17 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.28bn | 58.00 | 24.95 | 1.82 | 14.21 | 9.78 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Novocure Ltd | 509.34m | -207.04m | 1.29bn | 1.45k | -- | 3.56 | -- | 2.53 | -1.95 | -1.95 | 4.79 | 3.39 | 0.4358 | 3.80 | 6.91 | 350,542.30 | -17.71 | -7.74 | -20.71 | -8.95 | 74.81 | 77.22 | -40.65 | -14.69 | 5.56 | -- | 0.6108 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Spyre Therapeutics Inc | 886.00k | -338.79m | 1.30bn | 30.00 | -- | -- | -- | 1,469.78 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.32bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.33bn | 1.60k | -- | 0.3964 | -- | 1.79 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -152.63m | 1.35bn | 142.00 | -- | 3.31 | -- | -- | -2.08 | -2.08 | 0.00 | 5.34 | 0.00 | -- | -- | 0.00 | -33.72 | -26.04 | -36.09 | -27.45 | -- | -- | -- | -- | -- | -- | 0.023 | -- | -- | -- | -12.36 | -- | -- | -- |
| Arcus Biosciences Inc | 117.00m | -307.00m | 1.35bn | 577.00 | -- | 2.43 | -- | 11.53 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.35bn | 642.00 | 78.66 | 3.06 | 17.61 | 2.78 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.38bn | 155.00 | -- | 3.96 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Morphic Holding Inc | 521.00k | -152.10m | 1.38bn | 121.00 | -- | 1.96 | -- | 2,642.08 | -3.49 | -3.49 | 0.0119 | 14.01 | 0.001 | -- | 2.29 | 4,305.79 | -27.88 | -22.69 | -28.99 | -24.99 | -- | -- | -29,192.90 | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.40bn | 55.00 | -- | 2.14 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| ADMA Biologics Inc | 258.22m | -28.24m | 1.44bn | 624.00 | -- | 10.37 | -- | 5.57 | -0.1263 | -0.1263 | 1.14 | 0.5981 | 0.7621 | 1.01 | 12.03 | 413,806.10 | -8.33 | -24.80 | -9.60 | -28.00 | 34.44 | 17.02 | -10.94 | -51.31 | 1.69 | 0.924 | 0.4913 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Data as of Apr 19 2024. Currency figures normalised to Arcus Biosciences Inc's reporting currency: US Dollar USD
33.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 8.76m | 9.64% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.73m | 5.20% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.58m | 5.04% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.24m | 4.67% |
| Octagon Capital Advisors LPas of 31 Dec 2023 | 1.87m | 2.06% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.59m | 1.76% |
| AllianceBernstein LPas of 31 Dec 2023 | 1.19m | 1.31% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.14m | 1.26% |
| Woodline Partners LPas of 31 Dec 2023 | 1.04m | 1.14% |
| Suvretta Capital Management LLCas of 31 Dec 2023 | 957.30k | 1.05% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
